Pfiz­er stokes ru­mor mill with plan to raise $5B in debt; Lil­ly's CGRP Em­gal­i­ty wins speedy re­view for clus­ter headaches

Pfiz­er $PFE is rais­ing $5 bil­lion in debt, and in this heat­ed M&A en­vi­ron­ment, there’s quite a bit of buzz about what the mon­ey will be spent on. For the record, their state­ment says it will be used for gen­er­al cor­po­rate us­es plus debt re­struc­tur­ing. But that won’t stop the ru­mors on Twit­ter.

Lil­ly’s $LLY mi­graine drug is up for an­oth­er ap­proval. The treat­ment Em­gal­i­ty — one of the crop of re­cent­ly ap­proved CGRP in­hibitors used for mi­graine pre­ven­tion — has been grant­ed pri­or­i­ty re­view by the FDA to pre­vent episod­ic clus­ter headaches in adults. The un­der-rec­og­nized and of­ten mis­di­ag­nosed dis­or­der has no FDA-ap­proved pre­ven­ta­tive treat­ments so far.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.